MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-TN-02-0067567
Saimirra Innopharm Private Limited - pharma in Chennai, Tamil Nadu, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹132.6 Cr
▲ 65% YoY
Net profit · FY 2025
₹5.07 Cr
Net margin 3.8%
EBITDA · FY 2025
₹41.11 Cr
EBITDA margin 31%
Authorised capital
₹19.25 Cr
Registered with MCA
Paid-up capital
₹16 Cr
Issued & subscribed
Open charges
₹175.36 Cr
Satisfied ₹245.87 Cr
Company age
26 yrs
Est. 2000
Employees · EPFO
154
Provident fund records
About Saimirra Innopharm Private Limited
Data last updated:
Saimirra Innopharm Private Limited is a private limited company based in Chennai, Tamil Nadu, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 06 March 2000 and has been in existence for over 26 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN U24232TN2000PTC044315. Its GSTIN is 33AAECS3152L1ZD (Tamil Nadu). The company holds 5 GST registrations, of which 3 are active.
The company has an authorised share capital of ₹19.25 Cr and a paid-up capital of ₹16 Cr. It is led by directors including Shanmugam Muthusamy and Jaganathan Jayaseelan.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 288 & 299 SIDCO Estate Ambattur, Chennai, Tamil Nadu, India – 600098.
As per the financials filed for FY 2025, the company reported a revenue of ₹132.6 Cr, a growth of 65% compared to the previous year. For the same year it recorded a net profit of ₹5.07 Cr (net margin 3.8%) and EBITDA of ₹41.11 Cr (EBITDA margin 31%). Revenue has grown at a compounded annual rate (CAGR) of 25% over three years and 19% over five years.
The company has about 154 employees on its provident fund (EPFO) records.
The company is associated with 3 brands: Saimirra, Dhanasri Finvisory and JMP Advisors. As per MCA filings, the company has open charges of ₹175.36 Cr and satisfied charges of ₹245.87 Cr on record. Court records list 21 cases involving the company, including 6 filed by the company and 15 filed against it; 3 cases are pending. The company has 2 deals on record (1 funding round, 1 acquisition), with disclosed funding of ₹160 Cr; the latest was in April 2025. Its 9 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Vikram Thermo (India) Limited with revenue of ₹133.72 Cr.
Saimirra Innopharm Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-TN-02-0067567). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website saimirra.com.
Company details
CIN U24232TN2000PTC044315
Registration Number 044315
Incorporation Date 06 March 2000
ROC Chennai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-TN-02-0067567
Key People
Ayyavu Rajavel Alternate Director Shanmugam Muthusamy Director Jaganathan Jayaseelan Director Recognitions & Rankings of Saimirra Innopharm
Contact details
Saimirra Innopharm Private Limited's registered office is in Chennai, Tamil Nadu. Its website is saimirra.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address288 & 299 SIDCO Estate Ambattur, Chennai, Tamil Nadu, India – 600098
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Saimirra Innopharm Private Limited, buy the company report.
Comprehensive company report
Saimirra Innopharm Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Saimirra Innopharm operates multiple associated brands including Saimirra, Dhanasri Finvisory, and JMP Advisors. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufactures and exports pharmaceutical formulations, API, and CRO services for global markets. | saimirra.com | |
| Offers financial advisory, capital raising, and debt structuring for businesses worldwide. | dsfinv.in | |
| Provides tax advisory, litigation, and compliance for businesses in various sectors. | jmpadvisors.com |
Business activity
The main business activity of Saimirra Innopharm is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Saimirra Innopharm Private Limited, buy the company report.
Financials of Saimirra Innopharm Private Limited
FY 2024 filings availableSaimirra Innopharm Private Limited reported revenue of ₹132.6 Cr (up 65% YoY) for FY 2025.
Revenue · FY 2025
₹132.6 Cr ▲ 65%
Net profit · FY 2025
₹5.07 Cr margin 3.8%
EBITDA · FY 2025
₹41.11 Cr margin 31%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 65%
3 years · compounded
▲ 25%
5 years · compounded
▲ 19%
EBITDA CAGR growth
1 year
▲ 78%
3 years · compounded
▲ 76%
5 years · compounded
▲ 35%
Revenue has grown at a compounded annual rate (CAGR) of 19% over five years, including 65% growth in the latest year. EBITDA rose 78% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹41.11 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹5.07 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 31% | ||||
| Net Profit Margin | 3.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Saimirra Innopharm Private Limited, buy the company report.
Board of directors of Saimirra Innopharm Private Limited
Saimirra Innopharm has 6 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ayyavu Rajavel Also directs: Nuray Chemicals Private Limited, Delvin Surgicals Private Limited, Tindivanam Pharma Park Association and 5 more | Alternate Director | 22 Oct 2012 | 14 Years 0 Months | Current |
| Shanmugam Muthusamy Also directs: Nuray Chemicals Private Limited, Annamar Pharma LLP, Esjay Pharma Private Limited and 5 more | Director | 22 Oct 2012 | 14 Years 0 Months | Current |
| Jaganathan Jayaseelan Also directs: Durujaya Infrastructure LLP, Nuray Chemicals Private Limited, Clan Laboratories Private Limited and 5 more | Director | 18 Jul 2012 | 14 Years 3 Months | Current |
| Thanigainathan Thirumurugan | Director | 14 Jun 2013 | 13 Years 4 Months | Current |
| Bernice Sugirtha | Director | 09 Jul 2024 | 2 Years 3 Months | Current |
| Abhishek Jain Also directs: Biodeal Pharmaceuticals Limited, Harmony Organics Private Limited, 3 Gen Consulting Services Private Limited and 1 more | Nominee Director | 19 Jul 2025 | 1 Years 3 Months | Current |
Peer comparison
Saimirra Innopharm Private Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Vikram Thermo (India) Limited | ₹133.72 Cr (FY 2025) | 5.0% | Ahmedabad, Gujarat, India | |||
| Strassenburg Pharmaceuticals Private Ltd. | ₹133.69 Cr (FY 2025) | 13.0% | Kolkata, West Bengal, India | |||
| Hemmo Pharmaceuticals Private Limited | ₹133.32 Cr (FY 2021) | 45.0% | Mumbai, Maharashtra, India | |||
| Ordain Health Care Global Private Limited | ₹133.17 Cr (FY 2025) | -4.0% | Maduranthakam, Tamil Nadu, India | |||
| Makers Laboratories Ltd | ₹132.64 Cr (FY 2025) | 25.0% | Mumbai, Maharashtra, India | |||
| Saimirra Innopharm Private Limitedthis company | ₹132.6 Cr (FY 2025) | ₹5.07 Cr | 3.8% | 65.0% | 154 | Chennai, Tamil Nadu, India |
| Bengal Chemicals and Pharmaceuticals Ltd | ₹132.57 Cr (FY 2024) | 18.0% | Kolkata, West Bengal, India | |||
| Prosperity Drugs Private Limited | ₹131.43 Cr (FY 2025) | -1.0% | Solan, Himachal Pradesh, India | |||
| Dey's Medical Stores (Manufacturing) Ltd | ₹130.35 Cr (FY 2025) | -2.0% | Kolkata, West Bengal, India | |||
| Elder Prroject Limited | ₹129.37 Cr (FY 2022) | 18.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Saimirra Innopharm Private Limited, buy the company report.
Auditor
Saimirra Innopharm Private Limited is audited by Ramesh and Ramachandran for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Ramesh and Ramachandran | FY 2024 | 002981S |
Shareholding
The shareholding of Saimirra Innopharm Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Saimirra Innopharm Private Limited, buy the company report.
Charges & borrowings
Open charges
₹175.36 Cr
Satisfied charges
₹245.87 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 10 Apr 2025 | 101104921 | Others | ₹160 Cr | Open | |
| 31 May 2024 | 100945519 | Others | ₹15 Cr | Open | |
| 02 Feb 2024 | 100910612 | Hdfc Bank Limited | ₹36.16 Lakh | Open | |
| 24 Feb 2023 | 100706380 | Others | ₹165 Cr | Satisfied | |
| 25 Oct 2021 | 100491679 | Others | ₹2 Cr | Satisfied |
To see the full charge records of Saimirra Innopharm Private Limited, buy the company report.
Total charge records: 11 View all charges
Deals & funding
Saimirra Innopharm Private Limited has 2 deals on record (1 funding round, 1 acquisition), with disclosed funding of ₹160 Cr; the latest was in April 2025.
Total deals
2
Funding round
1
Acquisition
1
Disclosed funding
₹160 Cr
Deals on record (2 of 2)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2025 | Funding round | ₹160 Cr | Investors: Piramal Structured Finance |
| Dec 2012 | Acquisition | Undisclosed | Buyer: Clan Laboratories Private Limited Seller: Saimirra Innopharm Private Limited |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Saimirra Innopharm Private Limited has 21 court cases on record: 6 filed by Saimirra Innopharm, 15 filed against it. 3 cases are pending and 18 are disposed.
Total cases
21
Filed by the company
6
Filed against the company
15
Pending
3
Disposed
18
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 13 | 9 | 2 |
| District courts | 6 | 6 | 1 |
| Supreme Court | 1 | 0 | 0 |
| NCLT | 1 | 0 | 0 |
Cases on record (5 of 21)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, TAMIL NADU | Civil suit | Filed against the company by Novartis Healthcare Pvt Ltd., and 1 other | Disposed |
| District court, Tiruvallur, Tamil Nadu | Execution petition | Filed against the company by Ms. Ruby Organics Pvt. Ltd. | Disposed |
| Bombay High Court | Court case (TD) | Filed against the company by M/S. Rubyorganics Pvt. Ltd. | Disposed |
| Bombay High Court | Court case (APP) | Filed by the company against Rubyorganics Pvt. Ltd. | Disposed |
| Bombay High Court | Court case (NMA) | Filed by the company against Rubyorganics Pvt. Ltd. | Disposed |
To see the full case history of Saimirra Innopharm Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Saimirra Innopharm Private Limited was last rated by Crisil on 26 May 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 26 May 2020 |
To see the full credit ratings and regulatory alerts of Saimirra Innopharm Private Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Saimirra Innopharm Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Saimirra Innopharm Private Limited has a workforce of 154 employees on its EPFO records as of Mar 25, 2025, across 1 active EPFO establishment.
Employee count
154
Active EPFO establishments
1
Employee growth
-0.65%
GST
Saimirra Innopharm has 5 GST registrations: 3 active and 2 cancelled or inactive.
Total GSTINs
5
Active
3
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 33AAECS3152L1ZD | Tamil Nadu | Active | 01 Jul 2017 |
| 27AAECS3152L2Z5 | Maharashtra | Active | 08 Jan 2021 |
| 19AAECS3152L1Z3 | West Bengal | Active | 12 Jan 2021 |
To see the full GST registrations and return filing status of Saimirra Innopharm Private Limited, buy the company report.
Recent activity
Saimirra Innopharm Private Limited has 14 board changes on record since 2011: 6 appointments and 8 cessations. The latest: Abhishek Jain was appointed as Nominee Director on 19 Jul 2025.
Charges
A charge with Others of Rs. 160.00 Cr registered on 10 Apr 2025 with Charge ID 101104921 was modified on 11 Sep 2025.
Appointed
Abhishek Jain was appointed as Nominee Director.
Charges
A charge registered on 24 Feb 2023 via Charge ID 100706380 with Others was fully satisfied on 05 May 2025.
Charges
A charge with Others amounted to Rs. 160.00 Cr with Charge ID 101104921 was registered on 10 Apr 2025.
AGM
Saimirra Innopharm Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Appointed
Bernice Sugirtha was appointed as Director.
Charges
A charge with Others amounted to Rs. 15.00 Cr with Charge ID 100945519 was registered on 31 May 2024.
Filing
Saimirra Innopharm Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Chennai.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.36 Cr with Charge ID 100910612 was registered on 02 Feb 2024.
Charges
A charge with Others of Rs. 165.00 Cr registered on 24 Feb 2023 with Charge ID 100706380 was modified on 19 Oct 2023.
Charges
A charge registered on 30 Oct 2019 via Charge ID 100318053 with Others was fully satisfied on 03 Apr 2023.
Charges
A charge registered on 25 Oct 2021 via Charge ID 100491679 with Others was fully satisfied on 14 Mar 2023.
30 earlier events are in the company report.
Frequently asked questions
Saimirra Innopharm is an active private limited company based in Chennai, Tamil Nadu, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 06 March 2000 (26+ years old) and is registered under CIN U24232TN2000PTC044315.
Saimirra Innopharm has 6 current directors:
- Ayyavu Rajavel - Alternate Director
- Shanmugam Muthusamy - Director
- Jaganathan Jayaseelan - Director
- Thanigainathan Thirumurugan - Director
- Bernice Sugirtha - Director
- Abhishek Jain - Nominee Director
The latest financial statements of Saimirra Innopharm on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Saimirra Innopharm is 33AAECS3152L1ZD, registered in Tamil Nadu. The company has 5 GST registrations in all, of which 3 are active and 2 are cancelled or inactive. Other active GSTINs include 27AAECS3152L2Z5 (Maharashtra), 19AAECS3152L1Z3 (West Bengal).
The CIN (Corporate Identification Number) of Saimirra Innopharm is U24232TN2000PTC044315. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Saimirra Innopharm has 21 court cases on record: 6 filed by the company and 15 filed against it. 3 are pending. Most are in the high courts.
Saimirra Innopharm was incorporated on 06 March 2000, making it 26+ years old. It is registered with the Registrar of Companies, Chennai.
Saimirra Innopharm has 2 deals on record (1 funding round, 1 acquisition), with disclosed funding of ₹160 Cr; the latest was in April 2025.
The peers of Saimirra Innopharm by revenue are Vikram Thermo (India) Limited, Strassenburg Pharmaceuticals Private Ltd, Hemmo Pharmaceuticals Private Limited, Ordain Health Care Global Private Limited, Makers Laboratories Ltd and 4 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Abhishek Jain was appointed as Nominee Director on 19 Jul 2025. Bernice Sugirtha was appointed as Director on 09 Jul 2024. Thanigainathan Thirumurugan ceased to be Additional Director on 30 Sep 2013. Saimirra Innopharm has 14 board changes on record in total.
Yes, Saimirra Innopharm is registered as a medium enterprise under Udyam registration (number: UDYAM-TN-02-0067567).